Plasma legumain in familial hypercholesterolemia: associations with statin use and cardiovascular risk markers

References

• Dall E, Brandstetter H. Structure and function of legumain in health and disease. Biochimie. 2016;122:126–150. doi: 10.1016/j.biochi.2015.09.022.
   PubMed Web of Science ®Google Scholar
• Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–533. doi: 10.1038/s41586-021-03392-8.
   PubMed Web of Science ®Google Scholar
• Clerin V, Shih HH, Deng N, et al. Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis. Atherosclerosis. 2008;201(1):53–66. doi: 10.1016/j.atherosclerosis.2008.01.016.
   PubMed Web of Science ®Google Scholar
• Lunde NN, Holm S, Dahl TB, et al. Increased levels of legumain in plasma and plaques from patients with carotid atherosclerosis. Atherosclerosis. 2017;257:216–223. doi: 10.1016/j.atherosclerosis.2016.11.026.
   PubMed Web of Science ®Google Scholar
• Umei TC, Kishimoto Y, Aoyama M, et al. High plasma levels of legumain in patients with complex coronary lesions. J Atheroscler Thromb. 2020;27(7):711–717. doi: 10.5551/jat.52027.
   PubMed Web of Science ®Google Scholar
• Yang H, He Y, Zou P, et al. Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction. Cell Death Dis. 2020;11(11):1014. doi: 10.1038/s41419-020-03211-4.
   PubMed Web of Science ®Google Scholar
• Ozawa N, Sato Y, Mori Y, et al. Legumain promotes atherosclerotic vascular remodeling. Int J Mol Sci. 2019;20(9):2195. doi: 10.3390/ijms20092195.
   PubMed Web of Science ®Google Scholar
• Lunde NN, Gregersen I, Ueland T, et al. Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages. Atherosclerosis. 2020;296:74–82. doi: 10.1016/j.atherosclerosis.2019.12.008.
   PubMed Web of Science ®Google Scholar
• Gregersen I, Michelsen AE, Lunde NN, et al. Legumain in acute coronary syndromes: a substudy of the PLATO (platelet inhibition and patient outcomes). Trial. JAMA. 2020;9(17):e016360.
   Google Scholar
• Goldstein JL, Brown MS. Familial hypercholesterolemia: pathogenesis of a receptor disease. Johns Hopkins Med J. 1978;143(1):8–16.
   PubMedGoogle Scholar
• Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the european atherosclerosis society. Eur Heart J. 2013;34(45):3478–390a. doi: 10.1093/eurheartj/eht273.
   PubMed Web of Science ®Google Scholar
• Mundal L, Veierød MB, Halvorsen T, et al. Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study. Eur J Prev Cardiol. 2016;23(18):1962–1969. doi: 10.1177/2047487316666371.
   PubMed Web of Science ®Google Scholar
• Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425–2437. doi: 10.1093/eurheartj/ehv157.
   PubMed Web of Science ®Google Scholar
• Narverud I, Christensen JJ, Bakke SS, et al. Profiling of immune-related gene expression in children with familial hypercholesterolaemia. J Intern Med. 2020;287(3):310–321. doi: 10.1111/joim.13001.
   PubMed Web of Science ®Google Scholar
• Narverud I, Retterstøl K, Iversen PO, et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. Atherosclerosis. 2014;235(2):299–309. doi: 10.1016/j.atherosclerosis.2014.05.917.
   PubMed Web of Science ®Google Scholar
• Holven KB, Narverud I, Lindvig HW, et al. Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. Atherosclerosis. 2014;233(2):561–567. doi: 10.1016/j.atherosclerosis.2014.01.022.
   PubMed Web of Science ®Google Scholar
• Bekkering S, Stiekema LCA, Bernelot Moens S, et al. Treatment with statins does not revert trained immunity in patients with familial hypercholesterolemia. Cell Metab. 2019;30(1):1–2. doi: 10.1016/j.cmet.2019.05.014.
   PubMed Web of Science ®Google Scholar
• Øyri LKL, Hansson P, Bogsrud MP, et al. Delayed postprandial TAG peak after intake of SFA compared with PUFA in subjects with and without familial hypercholesterolaemia: a randomised controlled trial. Br J Nutr. 2018;119(10):1142–1150. doi: 10.1017/S0007114518000673.
   PubMed Web of Science ®Google Scholar
• Narverud I, Bogsrud MP, Øyri LKL, et al. Lipoprotein(a) concentration is associated with plasma arachidonic acid in subjects with familial hypercholesterolaemia. Br J Nutr. 2019;122(7):790–799. doi: 10.1017/S0007114519001600.
   PubMed Web of Science ®Google Scholar
• Narverud I, Halvorsen B, Nenseter MS, et al. Oxidized LDL level is related to gene expression of tumour necrosis factor super family members in children and young adults with familial hypercholesterolaemia. J Intern Med. 2013;273(1):69–78. doi: 10.1111/j.1365-2796.2012.02584.x.
   PubMed Web of Science ®Google Scholar
• Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia. Atherosclerosis. 2016;252:21–27. doi: 10.1016/j.atherosclerosis.2016.07.913.
   PubMed Web of Science ®Google Scholar
• Narverud I, Iversen PO, Aukrust P, et al. Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH. Thromb Res. 2013;131(2):178–182. doi: 10.1016/j.thromres.2012.11.008.
   PubMed Web of Science ®Google Scholar
• Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160(5):407–420. doi: 10.1093/aje/kwh236.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. R foundation for statistical computing., Vienna, Austria. 2022; Available from: URL https://www.R-project.org/.
   Google Scholar
• Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. JOSS. 2019. 2019;4(43):1686. doi: 10.21105/joss.01686.
   Google Scholar
• Jafari A, Qanie D, Andersen TL, et al. Legumain regulates differentiation fate of human bone marrow stromal cells and Is altered in postmenopausal osteoporosis. Stem Cell Reports. 2017;8(2):373–386. doi: 10.1016/j.stemcr.2017.01.003.
   PubMed Web of Science ®Google Scholar
• Wei W, Chen S, Huang J, et al. Serum legumain Is associated with peripheral artery disease in patients with type 2 diabetes. J Diabetes Res. 2021;2021:5651469–5651467. doi: 10.1155/2021/5651469.
   PubMed Web of Science ®Google Scholar
• Cojocaru M, Cojocaru IM, Silosi I. Lipoprotein-associated phospholipase A2 as a predictive biomarker of Sub-clinical inflammation in cardiovascular diseases. Maedica. 2010;5(1):51–55.
   PubMedGoogle Scholar
• Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337–345. doi: 10.1161/CIRCOUTCOMES.110.959247.
   PubMed Web of Science ®Google Scholar
• Stec JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. Circulation. 2000;102(14):1634–1638. doi: 10.1161/01.cir.102.14.1634.
   PubMed Web of Science ®Google Scholar
• Smith R, Solberg R, Jacobsen LL, et al. Simvastatin inhibits glucose metabolism and legumain activity in human myotubes. PLOS One. 2014;9(1):e85721-e85721. doi: 10.1371/journal.pone.0085721.
   Web of Science ®Google Scholar
• Wang ZH, Liu XL, Zhong M, et al. Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol. 2010;50(3):311–319. doi: 10.1177/0091270009340889.
   PubMed Web of Science ®Google Scholar
• Fang Y, Duan C, Chen S, et al. Increased legumain/Smad3 expression in atherosclerotic plaque of rat thoracic aorta. Biomed Pharmacother. 2019;119:109353. doi: 10.1016/j.biopha.2019.109353.
   PubMed Web of Science ®Google Scholar
• Jia D, Chen S, Bai P, et al. Cardiac resident macrophage-derived legumain improves cardiac repair by promoting clearance and degradation of apoptotic cardiomyocytes after myocardial infarction. Circulation. 2022;145(20):1542–1556. doi: 10.1161/CIRCULATIONAHA.121.057549.
   PubMed Web of Science ®Google Scholar